Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: October 18, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted

The purpose of this study is to determine the level of agreement between QuantiFeron -TB Gold test (QFT-G)and Tubeculin skin test (TST)for screening of latent tuberculosis in patients suffering from psoriasis.

Condition Intervention Phase
Other: Tuberculin skin test and Quantiferon -TB Gold test
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • The level of agreement between TST and QTF in patients with psoriasis in comparison with controls [ Time Frame: 3 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Levels of TST in patients with psoriasis in comparison with healthy controls [ Time Frame: 3 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: November 2010
Estimated Study Completion Date: August 2011
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Tuberculin skin test and Quantiferon -TB Gold test

    TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.

    QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions.

  Show Detailed Description


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients with psoriasis and psoriatic arthritis
  • Aged 18-90

Exclusion Criteria:

  • History of TB
  • Known allergy to TST
  • Current or past treatment with anti-TNF alpha
  Contacts and Locations
Please refer to this study by its identifier: NCT01223976

Contact: Ori Elkayam, MD 97236973668
Contact: Ayelet Brill 97236974837

Tel Aviv Medical Center Not yet recruiting
Tel Aviv, Israel, 64239
Contact: Ori Elkayam, M.D    97236973668   
Principal Investigator: Ori Elkayam         
Sub-Investigator: Hagit Mats         
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
  More Information

Responsible Party: Prof. Ori Elkayam, Tel Aviv Medical Center Identifier: NCT01223976     History of Changes
Other Study ID Numbers: 222-10
Study First Received: October 18, 2010
Last Updated: October 18, 2010
Health Authority: Israel: Ministry of Health

Keywords provided by Tel-Aviv Sourasky Medical Center:
latent tuberculosis psoriasis arthritis TST QTF
Screening of latent tuberculosis in psoriasis

Additional relevant MeSH terms:
Arthritis, Psoriatic
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases
Joint Diseases
Skin Diseases, Papulosquamous
Skin Diseases
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections processed this record on April 16, 2014